Provista Diagnostics, Inc., a Scottsdale, AZ- and NY-based molecular diagnostics company developing and commercializing diagnostic, prognostic and predictive tests for cancers affecting women, closed a $6.0m Series B financing.
Backers included existing investors.
The company, which has now raised $19.5m, intends to use the funds to expand the commercial market development for dtectDx-Breast, as well as pursue additional clinical trials it works toward 510K regulatory clearances for the assay.
Led by David Reese, Ph.D., President and CEO, Provista focuses on developing and commercializing proprietary diagnostic, prognostic and predictive tests for cancers affecting women, including breast and ovarian. The company also offers diagnostic testing and clinical laboratory services to the pharmaceutical and biotechnology industries through Provista Companion Diagnostics, a CLIA-accredited and GLP capable laboratory, licensed in 49 states to perform human clinical testing.
FinSMEs
17/04/2014